Amgen may face yet another setback with its controversial Repatha cholesterol-lowering drug because an influential nonprofit may soon lower its value rating for the medicine.
In a new report, the Institute for Clinical and Economic Review indicated that recently released clinical trial results prompted a reassessment, which will be lower than an initial cost-effective analysis issued two years ago. At the time, ICER pegged the value of the drug at between $5,400 and $7,700, which was notably lower than the $14,000 list price.
About the Author Reprints
